Apoptosis resistance in tumor cells

Cytotechnology

Volumn 27, Issue 1-3, 1998, Pages 293-308

  Mashima, Tetsuo ^a   Seimiya, Hiroyuki ^b   Chen, Zhihong ^b   Kataoka, Shiro ^c   Tsuruo, Takashi ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c KIRIN BREWERY CO LTD   (Japan)

Author keywords

Actin; Apoptosis resistance; Bcl 2; Caspase; JNK; Solid tumor

Indexed keywords

APOPTOSIS; APOPTOSIS RESISTANCE; CHEMOTHERAPY; MULTIDRUG RESISTANCE; SIGNALING PATHWAY; TUMOR CELL;

EID: 0032430651     PISSN: 09209069     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-2374-9_20     Document Type: Article

References (105)

1. Gros P, Ben Neriah YB, Croop JM and Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728-31.
2. Tsuruo T (1988) Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res 79: 285-96.
3. Pommier Y, Kerrigan D, Schwartz RE, Swack JA and McCurdy A (1986) Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075-81.
4. Raff MC (1992) Social controls on cell survival and cell death. Nature 356: 397-400.
5. Kerr JFR, Hormon B and Searle J (1974) An electronmicroscope study of cell deletion in the anuran tadpole tail during spontaneous metamorphosis with special reference to apoptosis of striated mustle fibres. J Cell Sci 14: 571-585.
6. Duvall E and Wyllie AH (1986) Death and the cell. Immunol Today?: 115-119.
7. Kerr JFR and Harmon BV (1991) Definition and incidence of apoptosis: an historical perspective. Apoptosis: the molecular basis of cell death 3: 5-29.
8. Wyllie AH, Morris RG, Smith AL and Dunlop D (1984) Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142: 67-77.
9. Cohen JJ and Duke RC (1984) Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 132: 38-42.
10. Kaufmann SH (1989) Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note 49: 5870-5878.
11. Gunji H, Kharbanda S and Kufe D (1991) Induction of Internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-b-D-arabinofuranosylcytosine. Cancer Res 51: 741-743.
12. Eastman A (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280.
13. Del Bino G, Bruno S, Yi PN and Darzynkiewicz Z (1992) Apoptotic cell death triggerd by camptothecin or teniposide: the cell cycle specificity and effects of ionizing radiation. Cell Prolif 25: 537-548.
14. Evans DL and Dive C (1993) Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and non-proliferating immature thymocytes. Cancer Res 53: 2133-2139.
15. Harmon BV, Takano YS, Winterford CM and Potten CS (1992) Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line. Cell Prolif 25: 523-536.
16. Bertrand R, Sarang M, Jenkin J, Kerrigan D and Pommier Y (1991) Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 51: 6280-6285.
17. Kharbanda S, Rubin E, Gunji H, Hinz H, Giovanella B and Pantazis P (1991) Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 51: 6636-6642.
18. Rubin E, Kharbanda S, Gunji H and Kufe D (1991) Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide. Mol Pharmacol 39: 697-701.
19. Gottesman MM (1987) Drug-resistant mutans: Selection and dominance analysis. Methods in Enzymology 151:113-121.
20. Kataoka S, Naito M, Tomida A and Tsuruo T (1994) Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells. Exp Cell Res 215: 199-205.
21. Vaux DL, Cory S and Adams JM (1988) Ed-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cell. Nature 335: 440-442.
22. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR and Aunins J (1992) A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356: 768-74.
23. Yuan J, Shaham S, Ledoux S, Ellis HM and Horvitz HR (1993) The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme 75: 641-652.
24. Henkart PA (1996) ICE family proteases: mediators of all apoptotic cell death? Immunity 4: 195-201.
25. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW and Yuan J (1996) Human ICE/CED-3 protease nomenclature. Cell 87: 171.
26. Miura M, Zhu H, Rotello R, Hartwieg EA and Yuan J (1993) Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75: 653-60.
27. Fernandes-Alnemri T, Litwack G and Alnemri ES (1994) CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 β-converting enzyme. J Biol Chem 269: 30761-4.
28. Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, Droge W, Krammer PH, Fiers W and Schulze-Osthoff K (1995) Requirement of an ICE/CED3 protease for Fas/APO-1-mediated apoptosis. Nature 375: 81-3.
29. Enari M, Hug H and Nagata S (1995) Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375: 78-81.
30. Tewari M and Dixit VM (1995) Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 270: 3255-60.
31. Tewari M, Telford WG, Miller RA and Dixit VM (1995) CrmA, a poxvirus-encoded serpin, inhibits cytotoxic T-lymphocyte-mediated apoptosis. J Biol Chem 270: 22705-8.
32. Boudreau N, Sympson CJ, Werb Z and Bissell MJ (1995) Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267: 891-3.
33. Dolle RE, Hoyer D, Prasad CV, Schmidt SJ, Helaszek CT, Miller RE and Ator MA (1994) PI aspartate-based peptide a-((2,6-dichlorobenzoyl)oxy)methyl ketones as potent time-dependent inhibitors of interleukin-1 β-converting enzyme. J Med Chem 37: 563-4.
34. Mashima T, Naito M, Kataoka S, Kawai H and Tsuruo T (1995) Aspartate-based inhibitor of interleukin-1β-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells. Biochem Biophys Res Commun 209: 907-15.
35. Mashima T, Naito M, Fujita N, Noguchi K and Tsuruo T (1995) Identification of actin as a substrate of ICE and an ICE-like protease and involvement of an ICE-like protease but not ICE in VP-16-induced U937 apoptosis. Biochem Biophys Res Commun 217: 1185-92.
36. Mashima T, Naito M, Noguchi K, Miller DK, NIcholson DW and Tsuruo T (1997) Actin Cleavage by CPP32/Apopain During the Development of Apoptosis. Oncogene 14: 1007-1012.
37. Noguchi K, Naito M, Kugoh H, Oshimura M, Mashima T, Fujita N, Yonehara S and Tsuruo T (1996) Chromosome 22 complements apoptosis in Fas- and TNF-resistant mutant UK110 Cells. Oncogene 13: 39-46.
38. Naito M, Nagashima K, Mashima T and Tsuruo T (1997) Phosphatidylserine externalization is a downstream event of interleukin-1β-converting enzyme family protease activation during apoptosis. Blood 89: 2060-2066.
39. Longthorne VL and Williams GT (1997) Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J 16: 3805-3812.
40. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976-3985.
41. Gu Y, Sarnecki C, Aldape RA, Livingston DJ and Su MS (1995) Cleavage of poly(ADP-ribose) polymerase by interleukin-1/J-converting enzyme and its homologs TX and Nedd-2. J Biol Chem 270: 18715-18718.
42. Nicholson DW, All A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M and Lazebnik YA (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
43. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen OS and Dixit VM (1995) Yama/CPP32;3, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-9.
44. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M and Wagner EF (1995) Mice lacking AD-PRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 9: 509-20.
45. Nicholson DW (1996) Nature Biotech 14: 297-301.
46. Rudel T and Bokoch GM (1997) Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276: 1571-1574.
47. Liu X, Zou H, Slaughter C and Wang X (1997) OFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89: 175-184.
48. Dérijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M and Davis RJ (1994) JNK1 : a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037.
49. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J and Woodgett JR (1994) The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369: 156-160.
50. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331.
51. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD., Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z and Kolesnick RN (1996) Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis. Nature 380: 75-79.
52. Chen YR, Wang X, Templeton D, Davis RJ and Tan TH (1996) The role of c-Jun N-terminal kinase (JNK) in apop-tosis induced by ultraviolet C and G radiation. J Biol Chem 271: 31929-31936.
53. Frisch SM, Vuori K, Kelaita D and Sicks S (1996) A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA. J Cell Biol 135: 1377-1382.
54. Seimiya H, Mashima T, Toho M and Tsuruo T (1997) c-Jun N-terminal Kinase-mediated Activation of Interleukin-1β-Converting Enzyme/CED-3-like Protease during Anticancer Drug-induced Apoptosis. J Biol Chem 272: 4631-4636.
55. 2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J Biol Chem 272: 10110-10116.
56. Davis RJ (1993) The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268: 14553-14556.
57. Kyriakis JM and Avruch J (1996) Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 271: 24313-24316.
58. Hibi M, Lin A, Smeal T, Minden A and Karin M (1993) Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7: 2135-2148.
59. Gupta S, Campbell D, Derijard B and Davis RJ (1995) Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389-393.
60. van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P and Angel P (1995) ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 14: 1798-1811.
61. Cavigelli M, Dolfi F, Claret FX and Karin M (1995) Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J 14: 5957-5964.
62. Whitmarsh AJ, Shore P, Sharrocks AD and Davis RJ (1995) Integration of MAP kinase signal transduction pathways at the serum response element. Science 269: 403-407.
63. Zinck R, Cahill MA, Kracht M, Sachsenmaier C, Hipskind RA and Nordheim A (1995) Protein synthesis inhibitors reveal differential regulation of mitogen-activated protein kinase and stress-activated protein kinase pathways that converge on Elk-1. Mol Cell Biol 15: 4930-4938.
64. Milne DM, Campbell LE, Campbell DG and Meek DW (1995) p53 is phosphorylated in vitro and in vivo by an ultra-violet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 270: 5511-5518.
65. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR and Kufe DW (1995) Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376: 785-788.
66. Saleem A, Datta R, Yuan ZM, Kharbanda S and Kufe D (1995) Involvement of stress-activated protein kinase in the cellular response to 1-β-D-Arabinofuranosylcytosine and other DNA-damaging agents. Cell Growth Differ 6: 1651-1658.
67. 2-terminal protein kinase pathway in the cellular response to Adriamycin and other chemotherapeutic drugs. J Biol Chem 271: 30950-30955.
68. Seimiya H, Sawabe T, Toho M and Tsuruo T (1995) Phorbol ester-resistant monoblastoid leukemia cells with a functional mitogen-activated protein kinase cascade but without responsive protein tyrosine phosphatases. Oncogene 11:2047-2054.
69. Froelich-Ammon SJ and Osheroff N (1995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 270: 21429-21432.
70. Kharbanda K, Pandey P, Ren R, Mayer B, Zon L and Kufe D (1995) c-Abl activation regulates induction of the SEKl/stress-activated protein kinase pathway in the cellular response to 1-b-D-arabinofuranosylcytosine. J Biol Chem 270:30278-30281.
71. Kharbanda S, Bharti A, Pel D, Wang J, Pandey P, Ren R, Weichselbaum R, Walsh CT and Kufe D (1996) The stress response to ionizing radiation involves c-Abl-dependent phosphorylation of SHPTP1. Proc Natl Acad Sci USA 93:6898-6901.
72. Angel P and Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochem Biophys Acta 1072: 129-157.
73. Seimiya H and Tsuruo T (1993) Differential expression of protein tyrosine phosphatase genes during phorbol ester-induced differentiation of human leukemia U937 cells. Cell Growth Differ 4: 1033-1039.
74. Estus S, Zaks WJ, Freeman RS, Gruda M, Bravo R and Johnson EM (1994) Altered gene expression in neurons during programmed cell death: Identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 127: 1717-1728.
75. Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, Yaniv M and Rubin LLA (1995) c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14: 927-39.
76. Sawai H, Okazaki T, Yamamoto H, Okano H, Takeda Y, Tashima M.Sawada H, Okuma M, Ishikura H, Umehara H and Domae N (1995) Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J Biol Chem 270: 27326-27331.
77. Bossy-Wetzel E, Bakiri L and Yaniv M (1997) Induction of apoptosis by the transcription factor c-Jun. EMBO J 16: 1695-1709.
78. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
79. Liu Z, Baskaran R, Lea-Chou ET, Wood LD, Chen Y, Karin M and Wang JYJ (1996) Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384: 273-276.
80. Nagata S (1997) Apoptosis by death factor. Cell 88: 355-365.
81. Liu Z, Hsu H, Goeddel DV and MK (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kB activation prevents cell death. Cell 87: 565-576.
82. Lenczowski JM, Dominguez L, Eder AM, King LB, Zacharchuk CM and Ashwell JD (1997) Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis. Mol Cell Biol 17: 170-181.
83. Natoli G, Costanzo A, lanni A, Templeton DJ, Wood-gett JR, Balsano C and Levrero M (1997) Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 275: 200-203.
84. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K and Gotoh Y (1997) Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275: 90-94.
85. Yang X, Khosravi-Far R, Chang HY and Baltimore D (1997) Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89: 1067-1076.
86. Su B, Jacinto E, Hibi M, Kallunki T, Karin M and Ben-Neriah Y (1994) JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77: 727-736.
87. Nishina H, Fischer KD, Radvanyi L, Shahinian A, Hakem R, Ruble EA, Bernstein A, Mak TW, Woodgett JR and Penninger JM (1997) Stress-signalling kinase Sekl protects thymocytes from apoptosis mediated by CD95 and CD3. Nature 385: 350-353.
88. Rodrigues GA, Park M and Schlessinger J (1997) Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J 16: 2634-2645.
89. Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R and Mercola D (1997) The Jun kinase/stress-activated protein kinase pathway fuctions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem272: 14041-14044.
90. Tsujimoto Y, Cossman J and Croce CM (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443.
91. Vaux DL, Cory S and Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cell. Nature 335: 440-442.
92. Strasser A, Harris AW and Cory S (1991) bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67: 888-899.
93. Miyashita T and Reed JC (1992) bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52: 5407-5411.
94. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thompson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608.
95. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G and Castle VP (1995) Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55: 2576-2582.
96. Bilim V, Tomita Y, Kawasaki T, Katagiri A, Imai T, Takeda M and KT (1996) Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J Nat Cancer Inst 88: 686-688.
97. Sumantran VN, Ealovega MW, Nunez G, Clarke MF and Wicha MS (1995) Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55:2507-2510.
98. Vogelstein B and Kinzler KW (1992) p53 function and dysfunction. Cell 70: 523-526.
99. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345-347.
100. Skladanowski A and Larsen AK (1997) Expression of wildtype p53 increases etoposide cytotoxicity in Ml myeloid leukemia cells by facilitated G2 to M transition: implications for gene therapy. Cancer Res 57: 818-823.
101. Lowe SW, Ruley HE, Jacks T and Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
102. Gorczyca W, Gong JBA Traganos F and Darzynkiewicz Z (1993) The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 53: 3186-3192.
103. Chen Z, Naito M, Mashima T and Tsuruo T (1996) Activation of Actin-cleavable ICE Family Protease CPP32 during Chemotherapeutic Agent-induced Apoptosis in Ovarian Carcinoma Cells. Cancer Res 56: 5224-29.
104. Chapman RS, Whetton AD, Dive C (1994) The suppression of drug-induced apoptosis by activation of v-ABL. Cancer Res 54: 5131-5137.
105. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385: 544-8.